Suppr超能文献

[肌肉减少症——老龄化社会中被忽视的问题]

[Sarcopenia - unnoticed problem of aging society].

作者信息

Kosiński Jakub, Blicharski Tomasz, Przepiórka-Kosińska Joanna, Dubiel Anna

机构信息

Katedra i Klinika Rehabilitacji i Ortopedii Uniwersytetu Medycznego w Lublinie, Lublin, Polska.

Katedra i Klinika Dermatologii, Wenerologii i Dermatologii Dziecięcej Uniwersytetu Medycznego w Lublinie, Lublin, Polska.

出版信息

Wiad Lek. 2019;72(9 cz 1):1655-1659.

Abstract

In the elderly, there is a reduction of the efficiency in many organs, including muscles. The weight, strength and power reduction of elderly muscles is defined as sarcopenia. The pathophysiology of sarcopenia is multifactorial, it can be influenced by intrinsic and extrinsic factors such as reduced caloric intake, denervation of muscle fibers - in the course of various neurodegenerative diseases, intracellular oxidative stress, hormonal disorders and others. The European Working Group on sarcopenia in the elderly published diagnostic criteria for sarcopenia in 2010, which should increase the recognition of this disease and speed up the treatment process. The best-confirmed methods of treatment of sarcopenia are nutritional hyperalimentation and resistance training. Pharmacological agents, i.e. selective androgen receptor modulators, and myostatin inhibitors are not sufficiently tested to be approved, by the FDA as a treatment regimen of sarcopenia.

摘要

在老年人中,包括肌肉在内的许多器官的效率都会降低。老年肌肉的重量、力量和功率下降被定义为肌肉减少症。肌肉减少症的病理生理学是多因素的,它会受到内在和外在因素的影响,如热量摄入减少、在各种神经退行性疾病过程中肌肉纤维去神经支配、细胞内氧化应激、激素紊乱等。欧洲老年肌肉减少症工作组在2010年发布了肌肉减少症的诊断标准,这应该会提高对这种疾病的认识并加快治疗进程。治疗肌肉减少症最得到充分证实的方法是营养支持和抗阻训练。药物制剂,即选择性雄激素受体调节剂和肌肉生长抑制素抑制剂,尚未经过充分测试,无法获得美国食品药品监督管理局(FDA)批准作为肌肉减少症的治疗方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验